
Feature|Videos|July 7, 2025
Harmonizing the Payer Perspective with Real-World Evidence
Expert panelists emphasize the importance of trusted data sources, strong payer partnerships, economic incentives, and AI-driven insights to address skepticism and support broader reimbursement and access strategies as payers balance real-world evidence with head-to-head clinical trials in their decision-making.
Advertisement
Episodes in this series

The trust gap between real-world evidence (RWE)/data and randomized controlled trials is growing. This episode examines when each evidence type is appropriate, how to reduce perceived bias in RWE, and how payer context varies by geography and structure. Insights from academic and payer partnerships show how joint research can establish credibility and unlock market access.
Key discussion topics include:
- Strategies for reducing payer skepticism about real-world data.
- The influence of health system structure on RWE acceptance.
- Use cases for RWE in confirmatory versus primary evidence roles.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Artisan Partners’ Director Calls for Novartis Board Shake-Up
2
The Agentic AI Revolution in Biopharma
3
340B Under Pressure: Inside Pharma's Push for Greater Clarity
4
Kura Oncology Spins Out Caspian Therapeutics With $50 Million to Test Menin Inhibition as a Disease-Modifying Approach to Diabetes
5





